Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities

J Med Chem. 2017 Jul 27;60(14):5969-5989. doi: 10.1021/acs.jmedchem.6b01851.

Matthew M Weiss, Thomas A Dineen, Isaac E Marx, Steven Altmann, Alessandro Boezio, Howard Bregman, Margaret Chu-Moyer, Erin F DiMauro, Elma Feric Bojic, Robert S Foti, Hua Gao, Russell Graceffa, Hakan Gunaydin, Angel Guzman-Perez, Hongbing Huang, Liyue Huang, Michael Jarosh, Thomas Kornecook ¹, Charles R Kreiman, Joseph Ligutti ¹, Daniel S La, Min-Hwa Jasmine Lin, Dong Liu ¹, Bryan D Moyer ¹, Hanh N Nguyen, Emily A Peterson, Paul E Rose, Kristin Taborn, Beth D Youngblood, Violeta Yu, Robert T Fremeau Jr

Affiliations

Affiliation

1 Department of Neuroscience, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.

PMID: 28287723 DOI: 10.1021/acs.jmedchem.6b01851

Abstract

Several reports have recently emerged regarding the identification of heteroarylsulfonamides as Na_V1.7 inhibitors that demonstrate high levels of selectivity over Other Na_V isoforms. The optimization of a series of internal Na_V1.7 leads that address a number of metabolic liabilities including bioactivation, PXR activation, as well as CYP3A4 induction and inhibition led to the identification of potent and selective inhibitors that demonstrated favorable pharmacokinetic profiles and were devoid of the aforementioned liabilities. The key to achieving this within a series prone to transporter-mediated clearance was the identification of a small range of optimal cLogD values and the discovery of subtle PXR SAR that was not lipophilicity dependent. This enabled the identification of compound 20, which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal of histamine-induced scratching bouts in mice.

Name
Email *

	Sorry, but the email address you supplied was invalid.